Until around 15 years ago, the forecast for spending included nominal annual growth rates of 5-10 per cent, but it was not real. It was not linked to anything. It could not be used to offset new listings because of Budget rules, which remain in place today, and it just made the program a target. It reflects a long-term, enduring dynamic. Nothing will change in the absence of reforming the system's basic architecture.
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Two new listings add treatment choices for growth hormone deficiency and people with type 1 diabetes
June 29, 2026 - - Latest News -
Officials highlight benefits but urge caution in rollout of AI-driven medical scribes
June 29, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News -
Surely this therapy is an example of our system at its absolute worst?
June 28, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News


